We are live on ! Find out more
INO icon

Inovio Pharmaceuticals

89 hedge funds and large institutions have $56.4M invested in Inovio Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 20 increasing their positions, 30 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more call options, than puts

Call options by funds: $5.24M | Put options by funds: $5.08M

2% more capital inflows, than outflows

Capital inflows: $7.87M | Capital outflows: $7.69M

0.98% less ownership

Funds ownership: 18.38% → 17.4% (-0.98%)

21% less funds holding

Funds holding: 113 → 89 (-24)

33% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 30

46% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 50

Holders
89
Holders Change
-24
Holders Change %
-21.24%
% of All Funds
1.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
20
Reduced
30
Closed
50
Calls
$5.24​M
Puts
$5.08​M
Net Calls
+$163​K
Net Calls Change
-⁠$121​K

INO Hedge Fund Activity: Q1 2024 in Review

89 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2024, worth a combined $56.4M — up 119% from $25.7M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of INO and 27 opened new positions — a net loss of 23 holders — while 30 trimmed existing stakes and 20 added.

The largest buyer was Millennium Management, adding an estimated $2.01M. The largest seller was GSA Capital Partners, cutting an estimated $2.04M.

  • 89 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2024, down from 113 in Q4 2023.
  • Funds reported $56.4M of Inovio Pharmaceuticals stock for Q1 2024, up 119% quarter-over-quarter.
  • 27 funds opened new Inovio Pharmaceuticals positions in Q1 2024 and 50 closed out, a net change of -23 holders.
  • The largest Inovio Pharmaceuticals buyer in Q1 2024 was Millennium Management, an estimated $2.01M added.
  • The largest Inovio Pharmaceuticals seller in Q1 2024 was GSA Capital Partners, an estimated $2.04M sold.

Based on aggregated 13F filings for Q1 2024.